Preclinical immunotherapy approaches in urothelium cancer

Poster Session 32

Sunday 17 March 12:15 - 13:45

Location: Green Area, Room 1

Chairs: K.W. Mouw, Boston (US)
        G. Pignot, Montreuil (FR)
        T.W. Todenhöfer, Tübingen (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 447

Mitomycin C triggers immunogenic cell death in bladder cancer cells

By: Oresta B.¹, Pozzi C.¹, Hurle R.², Lazzeri M.², Faccani C.¹, Colombo P.³, Elefante G.³, Casale P.², Guazzoni G.⁴, Rescigno M.⁵

¹Humanitas Clinical and Research Center, Laboratory of Mucosal Immunology and Microbiota, Rozzano, Italy, ²Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy, ³Humanitas Clinical and Research Center, Dept. of Pathology, Rozzano, Italy, ⁴Humanitas Clinical and Research Center, Humanitas University, Dept. of Urology, Rozzano, Italy, ⁵Humanitas Clinical and Research Center, Humanitas University, Laboratory of Mucosal Immunology and Microbiota, Rozzano, Italy

448

Cytotoxic T cell related gene expression signature predicts improved outcome in muscle-invasive urothelial bladder cancer patients following radical cystectomy and adjuvant chemotherapy

By: Eckstein M.¹, Wirtz R.², Strissel P.³, Pfannstiel C.¹, Wullweber A.¹, Lange F.¹, Erben P.⁴, Stoehr R.¹, Bertz S.¹, Geppert C.¹, Fuhrich N.¹, Weyerer V.¹, Taubert H.⁵, Erlmeier F.⁶, Breyer J.⁷, Otto W.⁷, Keck B.⁵, Wach S.⁵, Kunath F.⁵, Strick R.³, Hartmann A.¹, Wullich B.⁵, Sikic D.⁵, BRIDGE-Consortium Germany

¹University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Institute of Pathology, Erlangen, Germany, ²STRATIFYER Molecular Pathology, STRATIFYER Molecular Pathology, Cologne, Germany, ³University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Dept. of Gynecology and Obstetrics, Erlangen, Germany, ⁴Medical Faculty Mannheim, Ruprecht-Karls-Universität Heidelberg, Dept. of Urology Mannheim, Mannheim, Germany, ⁵University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Dept. of Urology and Pediatric Urology, Erlangen, Germany, ⁶TU Munich, Institute of Pathology, Munich, Germany, ⁷University Hospital, University of Regensburg, Dept. of Urology, Regensburg, Germany

449

The ataxia telangiectasia and Rad3-related kinase inhibitor AZD6738 overcomes cisplatin resistance in cisplatin-resistant bladder cancer cells
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>450</td>
<td>The genomic landscape of muscle-invasive bladder cancer enables a personalized in silico drug discovery</td>
<td>By: Krentel A.F., Singer F., Gibb E., Yang L., Davicioni E., Kruthof-De Julio M., Seiler R.</td>
<td>University Hospital Bern, Dept. of Urology, Bern, Switzerland, ETH Zürich, Clinical Bioinformatics Unit, Zurich, Switzerland, GenomeDX Biosciences, R&amp;D, Vancouver, Canada</td>
</tr>
<tr>
<td>451</td>
<td>Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment</td>
<td>By: Umezu D., Okada N., Sakoda Y., Adachi K., Eto M., Tamada K.</td>
<td>Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan, Graduate School of Medicine, Yamaguchi University, Dept. of Immunology, Ube, Japan</td>
</tr>
<tr>
<td>452</td>
<td>Targeting PHGDH exerts anti-oncogenic effects in bladder cancer</td>
<td>By: Yoshino H., Osako Y., Yonemori M., Tatarano S., Enokida H., Nakagawa M.</td>
<td>Graduate School of Medical, Kagoshima University, Dept. of Urology, Kagoshima, Japan</td>
</tr>
<tr>
<td>453</td>
<td>Next-gen STING-agonist like BCG confers enhanced immunogenicity and antitumor efficacy in vitro and in vivo</td>
<td>By: Bivalacqua T., Singh A., Praharaj M., Joice G., Yoshida T., Kates M., Mcconkey D., Bishai W.</td>
<td>Johns Hopkins University, School Of Medicine, Dept. Of Urology, Baltimore, United States of America, Johns Hopkins Medical Institutions, School of Medicine, Baltimore, United States of America, Johns Hopkins Medical Institutions, Brady Urological Institute, Baltimore, United States of America</td>
</tr>
<tr>
<td>455</td>
<td>Standard anticancer agents increase the sensitivity of human Vy9Vδ2T cell mediated cytotoxicity through NKG2D ligands in urinary bladder cancer</td>
<td>By: Shimizu T., Miyashita M., Fujihara A., Hongo F., Ukimura O., Ashihara E.</td>
<td>Matsushita Memorial Hospital, Dept. of Urology, Osaka, Japan, Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan, Kyoto Pharmaceutical University, Dept. of Clinical and Translational Physiology, Kyoto, Japan</td>
</tr>
<tr>
<td>456</td>
<td>Cobicistat, a potent CYP3A4 inhibitor, acts synergistically with oprozomib to cause endoplasmic reticulum stress in bladder cancer cells</td>
<td>By: Sato A., Asano T., Isono M., Okubo K.</td>
<td>National Defense Medical College, Dept. of Urology, Tokorozawa, Japan</td>
</tr>
</tbody>
</table>
457  
**Tumor targeting hyaluronic acid nanoparticles with combined phototherapy and hypoxia-activated chemotherapy for bladder preservation in MIBC**

By: Lin T.\(^1\), Qin H.\(^2\)
\(^1\)Nanjing Drum Tower Hospital, Medical school of Nanjing University, Dept. of Urology, Nanjing, China, \(^2\)Nanjing Drum Tower Hospital, Medical School of Nanjing University, Dept. of Urology, Nanjing, China

458  
**Systematic chemical screening identifies disulfiram as a repositionable drug that enhances sensitivity to cisplatin in bladder cancer: A summary of preclinical studies**

By: Kita Y.\(^1\), Kobayashi T.\(^1\), Teramoto Y.\(^2\), Tanaka R.\(^3\), Hamada A.\(^1\), Matsumoto K.\(^1\), Murakami K.\(^1\), Saito R.\(^1\), Nakayama K.\(^1\), Takano K.\(^4\), Akamatsu S.\(^1\), Yamasaki T.\(^1\), Inoue T.\(^1\), Tabata Y.\(^3\), Okuno Y.\(^5\), Ogawa O.\(^1\)
\(^1\)Kyoto University, Dept. of Urology, Kyoto, Japan, \(^2\)Kyoto University, Dept. of Clinical Pathology, Kyoto, Japan, \(^3\)Kyoto University, Dept. of Regeneration Science and Engineering, Kyoto, Japan, \(^4\)Hokkaido Institute of Public Health, Dept. of Environmental and Health Sciences, Hokkaido, Japan, \(^5\)Kyoto University, Dept. of Clinical System Onco-Informatics, Kyoto, Japan

459  
**Aberrant error-prone DNA damage repair as a potential therapeutic target for chemo-radiation resistant urothelial carcinoma**

By: Komura K., Inamoto T., Uehara H., Ibuki N., Minami K., Tsujino T., Azuma H.
Osaka Medical College, Dept. of Urology, Takatsuki city, Japan

13:34 - 13:41  
**Summary**

K.W. Mouw, Boston (US)